(Q35689146)

9 August 2017

1 reference

title

Pharmacogenomics of proton pump inhibitors (English)

1 reference

9 August 2017

1 reference

Takahisa Furuta

1

1 reference

9 August 2017

Naohito Shirai

2

1 reference

9 August 2017

Mitsushige Sugimoto

3

1 reference

9 August 2017

Kyoichi Ohashi

4

1 reference

9 August 2017

Takashi Ishizaki

5

1 reference

9 August 2017

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

181-202

1 reference

The pharmacology of the gastric acid pump: the H+,K+ ATPase

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

The life and death of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Cancer after exposure to metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.2.181.27483

10.1517/PHGS.5.2.181.27483

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference